02046nas a2200229   4500008004100000022001400041245009800055210006900153260000900222300001000231490000600241520135400247100002401601700002301625700002301648700002201671700002201693700001801715700002001733700002701753856003601780       2014                        eng d  a1948-175600aGene expression in thiazide diuretic or statin users in relation to incident type 2 diabetes.0 aGene expression in thiazide diuretic or statin users in relation  c2014  a22-300 v53 aThiazide diuretics and statins are used to improve cardiovascular outcomes, but may also cause type 2 diabetes (T2DM), although mechanisms are unknown. Gene expression studies may facilitate understanding of these associations. Participants from ongoing population-based studies were sampled for these longitudinal studies of peripheral blood microarray gene expression, and followed to incident diabetes. All sampled subjects were statin or thiazide users. Those who developed diabetes during follow-up comprised cases (44 thiazide users; 19 statin users), and were matched to drug-using controls who did not develop diabetes on several factors. Supervised normalization, surrogate variable analyses removed technical bias and confounding. Differentially-expressed genes were those with a false discovery rate Q-value<0.05. Among thiazide users, diabetes cases had significantly different expression of CCL14 (down-regulated 6%, Q-value=0.0257), compared with controls. Among statin users, diabetes cases had marginal but insignificantly different expression of ZNF532 (up-regulated 15%, Q-value=0.0584), CXORF21 (up-regulated 11%, Q-value=0.0584), and ZNHIT3 (up-regulated 19%, Q-value=0.0959), compared with controls. These genes comprise potential targets for future expression or mechanistic research on medication-related diabetes development.1 aSuchy-Dicey, Astrid1 aHeckbert, Susan, R1 aSmith, Nicholas, L1 aMcKnight, Barbara1 aRotter, Jerome, I1 aChen, Yd, Ida1 aPsaty, Bruce, M1 aEnquobahrie, Daniel, A  uhttps://chs-nhlbi.org/node/6603